Cargando…

Prognostic Role of Blood Markers in Primary Central Nervous System Lymphoma Patients Treated With High-Dose Methotrexate-Based Therapy

Purpose: Primary central nervous system lymphoma (PCNSL) is a rare type of extra-nodal non-Hodgkin lymphoma, but the prognostic value of blood parameters indicating systemic inflammation and nutritional status remains unknown. We aim to explore the prognostic role of blood parameters in PCNSL. Metho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Qian, Yang, Chunli, Fu, Chunxi, Wu, Wanchun, Wei, Yi, Zou, Liqun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117413/ https://www.ncbi.nlm.nih.gov/pubmed/33996552 http://dx.doi.org/10.3389/fonc.2021.639644

Ejemplares similares

Prognostic significance of the systemic immune-inflammation index in patients with extranodal natural killer/T-cell lymphoma
por: Hai, Tao, et al.
Publicado: (2023)

Successful Treatment of Central Nervous System Post-Transplant Lymphoproliferative Disease With a Reduced Dose of High-Dose Methotrexate
por: Albusoul, Linda, et al.
Publicado: (2022)

(18)F-FDG PET/CT Plays a Limited Role in Replacing Bone Marrow Biopsy for Newly Diagnosed Advanced-Stage Patients With Extranodal Natural Killer/T-Cell Lymphoma
por: Yang, Chunli, et al.
Publicado: (2022)

Editorial: Advances in the treatment of primary central nervous system lymphoma
por: Qian, Liren, et al.
Publicado: (2023)

High‐dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma
por: Akiyama, Hiroki, et al.
Publicado: (2016)

Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma
por: Bernard, S., et al.
Publicado: (2021)

A Systematic Review of High-Dose Methotrexate for Adults with Primary Central Nervous System Lymphoma
por: Villanueva, Gabriela, et al.
Publicado: (2023)

Rituximab with high-dose methotrexate is effective and cost-effective in newly diagnosed primary central nervous system lymphoma
por: Yuan, Xianggui, et al.
Publicado: (2022)

CD 5+ Peripheral B Cell Lymphoma With Transformation to CD 5+ Diffuse Large B Cell Lymphoma in the CNS: A Case Report Treated With Rituximab, High Dose Methotrexate, Cytarabine, and Intrathecal Methotrexate
por: Uczkowski, Dariusz, et al.
Publicado: (2022)

Primary Central Nervous System Lymphoma With Systemic Recurrence
por: Pandravada, Sasirekha, et al.
Publicado: (2021)

Impact of Central Nervous System International Prognostic Index on the Treatment of Diffuse Large B Cell Lymphoma
por: Ma'koseh, Mohammad, et al.
Publicado: (2021)

Relapsed Primary Central Nervous System Lymphoma: Current Advances
por: Tao, Kaiyan, et al.
Publicado: (2021)

Cerebrospinal fluid metabolic markers predict prognosis behavior of primary central nervous system lymphoma with high-dose methotrexate-based chemotherapeutic treatment
por: Zhou, Liying, et al.
Publicado: (2022)

Epidemiologic Characteristics, Prognostic Factors, and Treatment Outcomes in Primary Central Nervous System Lymphoma: A SEER-Based Study
por: Tang, Dongsheng, et al.
Publicado: (2022)

Curative effect of methotrexate combined with teniposide in the treatment of primary central nervous system lymphoma
por: Wang, Yi-Xia, et al.
Publicado: (2020)

Socioeconomic deprivation and survival outcomes in primary central nervous system lymphomas
por: Deng, Xiangyang, et al.
Publicado: (2022)

Primary central nervous system lymphoma in a rheumatoid arthritis patient treated with methotrexate: a case report
por: Shimada, Hiromi, et al.
Publicado: (2015)

Stereotactic Radiosurgery for Primary Central Nervous System Lymphoma
por: Wu, Susan Y, et al.
Publicado: (2023)

Complete Blood Count Score Model Predicts Inferior Prognosis in Primary Central Nervous System Lymphoma
por: Feng, Yuhua, et al.
Publicado: (2021)

Cardiovascular Death Risk in Primary Central Nervous System Lymphoma Patients Treated With Chemotherapy: A Registry-Based Cohort Study
por: Guan, Tianwang, et al.
Publicado: (2021)

ML-20 Outcome of high-dose methotrexate-based chemotherapy with or without Rituximab for primary central nervous system lymphoma
por: Takezaki, Tatsuya, et al.
Publicado: (2020)

ML-04 The influence of surgical intervention for high-dose Methotrexate chemotherapy in the patients with primary central nervous system lymphoma
por: Okamoto, Michinari, et al.
Publicado: (2020)

The Role of BAFF-R Signaling in the Growth of Primary Central Nervous System Lymphoma
por: Zhou, Xiaolan, et al.
Publicado: (2020)

Recent Progress on Primary Central Nervous System Lymphoma—From Bench to Bedside
por: Shao, Liang, et al.
Publicado: (2021)

Contrast-Enhanced MRI Texture Parameters as Potential Prognostic Factors for Primary Central Nervous System Lymphoma Patients Receiving High-Dose Methotrexate-Based Chemotherapy
por: Chen, Chaoyue, et al.
Publicado: (2019)

Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma
por: Fan, Ni, et al.
Publicado: (2017)

Reduced-dose whole-brain radiotherapy with tumor bed boost after upfront high-dose methotrexate for primary central nervous system lymphoma
por: Lee, Tae Hoon, et al.
Publicado: (2020)

Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma
por: Zhao, Defeng, et al.
Publicado: (2014)

Peripheral T-Cell Lymphomas Involving the Central Nervous System: A Report From the Czech Lymphoma Study Group Registry
por: Mocikova, Heidi, et al.
Publicado: (2022)

Factors Influencing the Response to High Dose Methotrexate-based Vincristine and Procarbazine Combination Chemotherapy for Primary Central Nervous System Lymphoma
por: Sung, Kang Hyun, et al.
Publicado: (2011)

Urine volume to hydration volume ratio is associated with pharmacokinetics of high‐dose methotrexate in patients with primary central nervous system lymphoma
por: Isono, Tetsuichiro, et al.
Publicado: (2021)

Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma
por: Sun, Xuefei, et al.
Publicado: (2017)

A novel inflammation-related prognostic model for predicting the overall survival of primary central nervous system lymphoma: A real-world data analysis
por: Wu, Zhentian, et al.
Publicado: (2023)

Real-World Impact of Surgical Excision on Overall Survival in Primary Central Nervous System Lymphoma
por: Deng, Xiangyang, et al.
Publicado: (2020)

High-Dose Methotrexate for the Treatment of Relapsed Central Nervous System Erdheim-Chester Disease
por: Ho, Prahlad, et al.
Publicado: (2014)

Treatment of Recurrent Posttransplant Lymphoproliferative Disorder of the Central Nervous System with High-Dose Methotrexate
por: Twist, Clare J., et al.
Publicado: (2013)

Hyperosmolar and methotrexate therapy avoiding surgery in the acute presentation of primary central nervous system lymphoma
por: Lee, Bryan S., et al.
Publicado: (2014)

Successful rapid drug desensitization to methotrexate in a patient with primary central nervous system lymphoma
por: Song, Kyung Mee, et al.
Publicado: (2018)

Histone deacetylase inhibition enhances the therapeutic effects of methotrexate on primary central nervous system lymphoma
por: Fujimoto, Kenji, et al.
Publicado: (2020)

Primary Central Nervous System T-cell Lymphoma as Methotrexate-associated Lymphoproliferative Disorders: Case Report
por: KAWANO, Hiroto, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5fk9cqte71guv3e3q0i4eo6nab